Adicet Bio Overview
- Founded
- 2014
- Status
- Public
- Employees
- 82
- Stock Symbol
- ACET
- Investments
- 2
- Share Price
- $12.56
- (As of Monday Closing)
Adicet Bio General Information
Description
Adicet Bio Inc is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 200 Constitution Drive
- Menlo Park, CA 94025
- United States
+1 (650) 000-0000
Adicet Bio Timeline
Adicet Bio Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.56 | $12.56 | $6.25 - $18.49 | $492M | 39.1M | 464K | -$2.00 |
Adicet Bio Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 61,458 | 167,671 | ||
| Revenue | 9,672 | 17,903 | 995 | 8,181 |
| EBITDA | (53,843) | (38,918) | (27,819) | (9,209) |
| Net Income | (55,144) | (36,678) | (28,138) | (9,299) |
| Total Assets | 257,195 | 153,835 | 81,587 | |
| Total Debt | 20,535 | 21,639 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Adicet Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.
Request a free trialAdicet Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.
Request a free trialAdicet Bio Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Adicet Bio Inc is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer
Drug Discovery
Menlo Park, CA
82
As of 2020
00000
00000000
00000
00000000
liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000000000000
Gaithersburg, MD
00
As of 0000
00000
0000
0000-00-00
00000000
00000
0000000
luptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pro
0000 000000000
Philadelphia, PA
00
As of 0000
00000
0000
0000-00-00
00000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAdicet Bio Competitors (33)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 0000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000000 | Formerly VC-backed | Tübingen, Germany | 000 | 00000 | 000000000 | 00000 |
Adicet Bio Patents
Adicet Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3126896-A1 | Methods for selective in vivo expansion of .gamma. .delta. t-cell populations and compositions thereof | Pending | 03-Dec-2018 | 00000000000 | |
| AU-2019394877-A1 | Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof | Pending | 03-Dec-2018 | 000000000 | |
| EP-3890757-A1 | Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof | Pending | 03-Dec-2018 | 00000000000 | |
| AU-2019354395-A1 | Compositions and methods regarding engineered and non-engineered γδ -t cells for treatment of solid tumors | Pending | 01-Oct-2018 | 0000000000 | |
| AU-2019354391-A1 | Compositions and methods regarding engineered and non- engineered γδ-τ cells for treatment of hematological tumors | Pending | 01-Oct-2018 | C12N15/62 |
Adicet Bio Executive Team (14)
Adicet Bio Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrew Sinclair Ph.D | Self | Board Member | 000 0000 |
| Aya Jakobovits Ph.D | Adicet Bio | Board Member | 000 0000 |
| Bastiano Sanna Ph.D | Self | Board Member | 000 0000 |
| Carl Gordon Ph.D | Self | Board Member | 000 0000 |
| Chen Schor | Adicet Bio | Chief Executive Officer & Board Member | 000 0000 |
Adicet Bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAdicet Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.
Request a free trialAdicet Bio Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 | 15-Sep-2020 | 0000000000 | 0000 | Biotechnology | 0000 0000 |
| Applied Immune Technologies | 27-Jan-2016 | Merger/Acquisition | Drug Discovery | 000 00000 |